Emerging Therapies: a look at the current data: NefIgArd study

Author(s):

Jonathan Barratt, PhD, FRCP,Anuja Java, MD

Key Takeaways

Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Clinical indicators like tumor size, stage, and overall health status are crucial in assessing disease outcomes.
Personalized medicine utilizes biomarkers to customize treatment plans, improving therapeutic efficacy and patient survival.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

EP: 1.Overview of IgAN and Its Common Symptoms

EP: 2.IgAN Progression

EP: 3.IgAN vs Other Glomerular Diseases

EP: 4.Biomarkers for IgAN

EP: 5.Genetic Screening for IgAN

EP: 6.Impact of IgAN on Quality of Life

EP: 7.Misdiagnosis and Barriers to Early Detection of IgAN

EP: 8.Differential Diagnoses of IgAN

EP: 9.Significance of Proteinuria for Potential IgAN

EP: 10.Proteinuria Variability and IgAN Diagnosis

EP: 11.Biomarkers and Improving IgAN Diagnostic Accuracy

EP: 12.Primary Treatment Goals for Patients With IgAN

EP: 13.Proteinuria Reduction in Long-Term Kidney Damage Prevention

EP: 14.Symptoms Management and Targeting the Root Cause of IgAN

EP: 15.Unmet Needs in Current IgAN Treatment

EP: 16.Prospective Improvements of Existing IgAN Therapies

EP: 17.Safety of IgAN Treatments

EP: 18.The Promise of Emerging IgAN Therapies

EP: 19.Emerging Therapies: a look at the current data: ALIGN

EP: 20.Emerging Therapies: a look at the current data: APPLAUSE

EP: 21.Emerging Therapies: a look at the current data: PROTECT study

Now Viewing

EP: 22.Emerging Therapies: a look at the current data: NefIgArd study

EP: 23.Implementing New IgAN Therapies Into Clinical Practice

EP: 24.Shared Decision-Making for IgAN Treatment

EP: 25.Summary and Closing Remarks

In the phase 3 ALIGN trial (NCT04573478), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?